title: The Innovative Medicines Initiative: an engine for regulatory science.
abstract: Since its launch in 2008, the Innovative Medicines Initiative has catalysed the formation of many consortia to address challenges in drug development and regulation. As it moves into its second phase, we highlight key outcomes so far and the lessons learned.
authors.affiliation: Innovative Medicines Initiative, B-1060 Brussels, Belgium.
authors.forename: Michel
authors.initials: M
authors.lastname: Goldman
authors.affiliation: Innovative Medicines Initiative, B-1060 Brussels, Belgium.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Seigneuret
authors.affiliation: European Medicines Agency, 30 Churchill Place, Canary Wharf, London E14 5EU, UK.
authors.forename: Hans-Georg
authors.initials: HG
authors.lastname: Eichler
mesh_terms: D035843:Biomedical Research / Q000331:legislation & jurisprudence / Q000639:trends; D002986:Clinical Trials as Topic / Q000331:legislation & jurisprudence / Q000639:trends; D055808:Drug Discovery / Q000331:legislation & jurisprudence* / Q000639:trends; D004345:Drug Industry / Q000331:legislation & jurisprudence* / Q000639:trends; D005062:European Union; D006801:Humans; D055818:Public-Private Sector Partnerships / Q000331:legislation & jurisprudence* / Q000639:trends